To view CARDENE® I.V. (nicardipine hydrochloride) full prescribing information, click a link below.

CARDENE I.V. 40 mg in 200 mL (0.2 mg/mL) 0.83% Sodium Chloride or 5% Dextrose

CARDENE I.V. 20 mg in 200 mL (0.1 mg/mL) 0.86% Sodium Chloride or 4.8% Dextrose

CARDENE I.V. 25 mg in 10 mL (2.5 mg/mL)

To view PDF documents, you must have Adobe® Reader®. Click here to download it for free. Adobe® and Reader® are registered trademarks of Adobe Systems Incorporated.

Indication

CARDENE® I.V. (nicardipine hydrochloride) Premixed Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits.1

Important Safety Information

CARDENE I.V. is contraindicated in patients with advanced aortic stenosis.

Hypotension and reflex tachycardia may potentially occur during treatment with CARDENE I.V.; therefore, close monitoring of blood pressure and heart rate is required. If unacceptable hypotension or tachycardia occurs, the infusion should be discontinued.

Slow titration of CARDENE I.V. is recommended in patients with heart failure or significant left ventricular dysfunction, particularly in combination with a beta-blocker.

Close monitoring of response to CARDENE I.V. is advised in patients with angina, heart failure, impaired hepatic function, or renal impairment.

To reduce the possibility of venous thrombosis, phlebitis, local irritation, and extravasation, administer CARDENE I.V. through large peripheral veins or central veins rather than arteries or small peripheral veins. If CARDENE I.V. is administered in a peripheral vein, to minimize the risk of venous irritation, change the site of infusion every 12 hours.

The most common adverse reactions (>3%) are headache, nausea/vomiting, hypotension, and tachycardia.

Please see full Prescribing Information.

References: 1. CARDENE I.V. (nicardipine hydrochloride) Premixed Injection Prescribing Information. Bedminster, NJ: EKR Therapeutics, Inc; 2011.